Advances in the Renin Angiotensin System. Focus on Angiotensin-Converting Enzyme 2 and Angiotensin-(1-7).

Advances in Pharmacology

Volumn 59, Issue C, 2010, Pages 197-233

  Ferrario, Carlos M ^a   Ahmad, Sarfaraz ^a   Joyner, Janae ^a   Varagic, Jasmina ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

ACE; ACE2; ACE2 KO; Ang II; Angiotensin converting enzyme 2; Angiotensin II; Angiotensin (1 7); CHO; Heart failure; HrACE2; Hypertension; LV; Mas R; MDCK; Mrg; RACE2; Renal function; SHR

Indexed keywords

ANGIOTENSIN CONVERTING ENZYME 2; ANGIOTENSIN II; ANGIOTENSIN[1-7]; ANGIOTENSIN DERIVATIVE; ANGIOTENSIN I; ANGIOTENSIN I (1-7); ANGIOTENSIN RECEPTOR; ANTIHYPERTENSIVE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PEPTIDE FRAGMENT;

BLOOD VESSEL; BOOK; CARDIOVASCULAR FUNCTION; ECLAMPSIA; ENZYME ACTIVITY; ENZYME KINETICS; ENZYME LOCALIZATION; ENZYME STRUCTURE; ESSENTIAL HYPERTENSION; HEART; HEMODYNAMICS; HORMONE ACTION; HUMAN; NONHUMAN; PREGNANCY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RENAL PROTECTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIGNAL TRANSDUCTION; ANIMAL; ANTIBODY SPECIFICITY; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CHEMISTRY; DRUG EFFECTS; ENZYMOLOGY; FEMALE; KIDNEY; MALE; METABOLISM; MOUSE; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREECLAMPSIA; RAT;

ANGIOTENSIN I; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANGIOTENSINS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; FEMALE; HUMANS; KIDNEY; MALE; MICE; ORGAN SPECIFICITY; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PRE-ECLAMPSIA; PREGNANCY; RATS; RECEPTORS, ANGIOTENSIN; RENIN-ANGIOTENSIN SYSTEM;

EID: 77957374580     PISSN: 10543589     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1054-3589(10)59007-0     Document Type: Chapter

References (306)

1. Agata J., Ura N., Yoshida H., Shinshi Y., Sasaki H., Hyakkoku M., et al. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme. Hypertension Research 2006, 29:865-874.
2. Alenina N., Xu P., Rentzsch B., Patkin E.L., Bader M. Genetically altered animal models for mas and angiotensin-(1-7). Experimental Physiology 2008, 93:528-537.
3. Alfany-Fernandez I., Casillas-Ramirez A., Bintanel-Morcillo M., Brosnihan K.B., Ferrario C.M., Serafin A., et al. Therapeutic targets in liver transplantation: Angiotensin II in nonsteatotic grafts and angiotensin-(1-7) in steatotic grafts. American Journal of Transplantation 2009, 9:439-451.
4. Almeida A.P., Frabregas B.C., Madureira M.M., Santos R.J., Campagnole-Santos M.J., Santos R.A. Angiotensin-(1-7) potentiates the coronary vasodilatatory effect of bradykinin in the isolated rat heart. Brazilian Journal of Medical and Biological Research 2000, 33:709-713.
5. Altundag K., Altundag O., Akyurek S., Silay K., Turen S. Angiotensin 1-7 and risk for breast cancer recurrence. Cancer Chemotherapy Pharmacology 2006, 58:283.
6. Andreatta-van L.S., Romero M.F., Khosla M.C., Douglas J.G. Modulation of phospholipase A2 activity and sodium transport by angiotensin-(1-7). Kidney International 1993, 44:932-936.
7. Anton L., Merrill D.C., Neves L.A., Brosnihan K.B. Angiotensin-(1-7) inhibits in vitro endothelial cell tube formation in human umbilical vein endothelial cells through the AT(1-7) receptor. Endocrine 2007, 32:212-218.
8. Anton L., Merrill D.C., Neves L.A., Diz D.I., Corthorn J., Valdes G., et al. The uterine placental bed renin-angiotensin system in normal and preeclamptic pregnancy. Endocrinology 2009, 150:4316-4325.
9. August P., Lenz T., Ales K.L., Druzin M.L., Edersheim T.G., Hutson J.M., et al. Longitudinal study of the renin-angiotensin-aldosterone system in hypertensive pregnant women: Deviations related to the development of superimposed preeclampsia. American Journal of Obstetrics and Gynecology 1990, 163:1612-1621.
10. Averill D.B., Ishiyama Y., Chappell M.C., Ferrario C.M. Cardiac angiotensin-(1-7) in ischemic cardiomyopathy. Circulation 2003, 108:2141-2146.
11. Baker P.N., Broughton P.F., Symonds E.M. Platelet angiotensin II binding and plasma renin concentration, plasma renin substrate and plasma angiotensin II in human pregnancy. Clinical Science (London) 1990, 79:403-408.
12. Baker P.N., Broughton P.F., Symonds E.M. Longitudinal study of platelet angiotensin II binding in human pregnancy. Clinical Science (London) 1992, 82:377-381.
13. Baracho N.C., Simoes-e-Silva A.C., Khosla M.C., Santos R.A. Effect of selective angiotensin antagonists on the antidiuresis produced by angiotensin-(1-7) in water-loaded rats. Brazilian Journal of Medical and Biological Research 1998, 31:1221-1227.
14. Batlle M., Roig E., Perez-Villa F., Lario S., Cejudo-Martin P., Garcia-Pras E., et al. Increased expression of the renin-angiotensin system and mast cell density but not of angiotensin-converting enzyme II in late stages of human heart failure. The Journal of Heart and Lung Transplantation 2006, 25:1117-1125.
15. Batlle D., Soler M.J., Wysocki J. New aspects of the renin-angiotensin system: Angiotensin-converting enzyme 2-a potential target for treatment of hypertension and diabetic nephropathy. Current Opinion in Nephrology and Hypertension 2008, 17:250-257.
16. Benter I.F., Diz D.I., Ferrario C.M. Cardiovascular actions of angiotensin(1-7). Peptides 1993, 14:679-684.
17. Benter I.F., Diz D.I., Ferrario C.M. Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). Hypertension 1995, 26:1138-1144.
18. Benter I.F., Ferrario C.M., Morris M., Diz D.I. Antihypertensive actions of angiotensin-(1-7) in spontaneously hypertensive rats. The American Journal of Physiology 1995, 269:H313-H319.
19. Benter I.F., Yousif M.H., Cojocel C., Al-Maghrebi M., Diz D.I. Angiotensin-(1-7) prevents diabetes-induced cardiovascular dysfunction. American Journal of Physiology. Heart and Circulatory Physiology 2007, 292:H666-H672.
20. Benter I.F., Yousif M.H., Dhaunsi G.S., Kaur J., Chappell M.C., Diz D.I. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. American Journal of Nephrology 2008, 28:25-33.
21. Berti D.A., Morano C., Russo L.C., Castro L.M., Cunha F.M., Zhang X., et al. Analysis of intracellular substrates and products of thimet oligopeptidase in human embryonic kidney 293 cells. The Journal of Biological Chemistry 2009, 284:14105-14116.
22. Block C.H., Santos R.A., Brosnihan K.B., Ferrario C.M. Immunocytochemical localization of angiotensin-(1-7) in the rat forebrain. Peptides 1988, 9:1395-1401.
23. Botelho-Santos G.A., Sampaio W.O., Reudelhuber T.L., Bader M., Campagnole-Santos M.J., Souza dos Santos R.A. Expression of an angiotensin-(1-7)-producing fusion protein in rats induced marked changes in regional vascular resistance. American Journal of Physiology. Heart and Circulatory Physiology 2007, 292:H2485-H2490.
24. Boucher R., Demassieux S., Garcia R., Gutkowska Y., Genest J. The tonin-angiotensin II system (article in French). Union Medical Cancer 1977, 106:502-507.
25. Brosnihan K.B. Effect of the angiotensin-(1-7) peptide on nitric oxide release. American Journal of Cardiology 1998, 82:17S-19S.
26. Brosnihan K.B., Li P., Ferrario C.M. Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. Hypertension 1996, 27:523-528.
27. Brosnihan K.B., Li P., Tallant E.A., Ferrario C.M. Angiotensin-(1-7): A novel vasodilator of the coronary circulation. Biological Research 1998, 31:227-234.
28. Brunner H.R., Gavras H., Ribeiro A.B., Posternak L. Angiotensin II blockade in normal man and patients with essential hypertension. Blood pressure effects depending on renin and sodium balance. Progress in Biochemical Pharmacology 1976, 12:145-162.
29. Bumpus F.M. Mechanisms and sites of action of newer angiotensin agonists and antagonists in terms of activity and receptor. Federation Proceedings 1977, 36:2128-2132.
30. Bumpus F.M., Husain A., Smeby R.R. Extended forms of brain angiotensins and other peptide hormones. Clinical and Experimental Hypertension. Part A 1984, 6:2101-2106.
31. Bumpus F.M., Khosla M.C. Inhibition of the pressor and aldosterone-releasing effects of angiotensin II. Clinical Science and Molecular Medicine Supplement 1975, 2:15s-18s.
32. Bumpus F.M., Smeby R.R., Sweet C., Ferrario C.M., Khosla M.C. Use of angiotensin II antagonists in experimental hypertension. Circulation Research 1973, 32(Suppl. 8):5. -5.
33. Burgelova M., Vanourkova Z., Thumova M., Dvorak P., Opocensky M., Kramer H.J., et al. Impairment of the angiotensin-converting enzyme 2-angiotensin-(1-7)-mas axis contributes to the acceleration of two-kidney, one-clip goldblatt hypertension. Journal of Hypertension 2009, 27:1988-2000.
34. Burrell L.M., Risvanis J., Kubota E., Dean R.G., MacDonald P.S., Lu S., et al. Myocardial infarction increases ACE2 expression in rat and humans. European Heart Journal 2005, 26:369-375.
35. Byku M., Macarthur H., Westfall T.C. Inhibitory effects of angiotensin-(1-7) on the nerve stimulation-induced release of norepinephrine and neuropeptide Y from the mesenteric arterial bed. American Journal of Physiology. Heart and Circulatory Physiology 2010, 298:H457-H465.
36. Calo L.A., Schiavo S., Davis P.A., Pagnin E., Mornino P., D'Angelo A., et al. ACE2 and angiotensin 1-7 are increased in a human model of cardiovascular hyporeactivity: Pathophysiological implications. Journal of Nephrology 2010, 23(4):472-477.
37. Campagnole-Santos M.J., Diz D.I., Ferrario C.M. Actions of angiotensin peptides after partial denervation of the solitary tract nucleus. Hypertension 1990, 15:I34-I39.
38. Campagnole-Santos M.J., Diz D.I., Santos R.A., Khosla M.C., Brosnihan K.B., Ferrario C.M. Cardiovascular effects of angiotensin-(1-7) injected into the dorsal medulla of rats. The American Journal of Physiology 1989, 257:H324-H329.
39. Campbell D.J., Duncan A.M., Kladis A., Harrap S.B. Angiotensin peptides in spontaneously hypertensive and normotensive donryu rats. Hypertension 1995, 25:928-934.
40. Campbell D.J., Lawrence A.C., Towrie A., Kladis A., Valentijn A.J. Differential regulation of angiotensin peptide levels in plasma and kidney of the rat. Hypertension 1991, 18:763-773.
41. Carvalho L.T., Nascimento E.A., Teixeira F.O., Nagaoka M.R., Borges D.R., Kouyoumdjian M. Hepatic conversion of angiotensin I and the portal hypertensive response to angiotensin II in normal and regenerating liver. Journal of Gastroenterology and Hepatology 2007, 22:1543-1548.
42. Castro C.H., Santos R.A., Ferreira A.J., Bader M., Alenina N., Almeida A.P. Evidence for a functional interaction of the angiotensin-(1-7) receptor mas with AT1 and AT2 receptors in the mouse heart. Hypertension 2005, 46:937-942.
43. Castro-Chaves P., Pintalhao M., Fontes-Carvalho R., Cerqueira R., Leite-Moreira A.F. Acute modulation of myocardial function by angiotensin 1-7. Peptides 2009, 30:1714-1719.
44. Cemassieux S., Boucher R., Crise C., Genest J. Purification and characterization of tonin. Canadian Journal of Biochemistry 1976, 54:788-795.
45. Chappell M.C. Does ACE2 contribute to the development of hypertension?. Hypertension Research 2010, 33:107-109.
46. Clark M.A., Tallant E.A., Diz D.I. Downregulation of the AT1A receptor by pharmacologic concentrations of angiotensin-(1-7). Journal of Cardiovascular Pharmacology 2001, 37:437-448.
47. Clark M.A., Tallant E.A., Tommasi E., Bosch S., Diz D.I. Angiotensin-(1-7) reduces renal angiotensin II receptors through a cyclooxygenase-dependent mechanism. Journal of Cardiovascular Pharmacology 2003, 41:276-283.
48. Coelho M.S., Lopes K.L., Freitas R.D., de Oliveira-Sales E.B., Bergasmaschi C.T., Campos R.R., et al. High sucrose intake in rats is associated with increased ACE2 and angiotensin-(1-7) levels in the adipose tissue. Regulatory Peptides 2010, 162(1-3):61-67.
49. Crackower M.A., Sarao R., Oudit G.Y., Yagil C., Kozieradzki I., Scanga S.E., et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002, 417:822-828.
50. Dantas A.P., Sandberg K. Regulation of ACE2 and ANG-(1-7) in the aorta: New insights into the renin-angiotensin system in the control of vascular function. American Journal of Physiology-Heart and Circulatory Physiology 2005, 289:H980-H981.
51. Davie A.P., McMurray J.J. Effect of angiotensin-(1-7) and bradykinin in patients with heart failure treated with an ACE inhibitor. Hypertension 1999, 34:457-460.
52. De Mello W.C. Angiotensin (1-7) re-establishes impulse conduction in cardiac muscle during ischaemia-reperfusion. The role of the sodium pump. Journal of the Renin-Angiotensin-Aldosterone System 2004, 5:203-208.
53. De Mello W.C. Cell swelling, impulse conduction, and cardiac arrhythmias in the failing heart. Opposite effects of angiotensin II and angiotensin (1-7) on cell volume regulation. Molecular and Cellular Biochemistry 2009, 330:211-217.
54. De Mello W.C. Opposite effects of angiotensin II and angiotensin (1-7) on impulse propagation, excitability and cardiac arrhythmias. Is the overexpression of ACE2 arrhythmogenic?. Regulatory Peptides 2009, 153:7-10.
55. De Mello W.C., Ferrario C.M., Jessup J.A. Beneficial versus harmful effects of angiotensin (1-7) on impulse propagation and cardiac arrhythmias in the failing heart. Journal of the. Renin-Angiotensin-Aldosterone System 2007, 8:74-80.
56. De Souza A.M., Lopes A.G., Pizzino C.P., Fossari R.N., Miguel N.C., Cardozo F.P., et al. Angiotensin II and angiotensin-(1-7) inhibit the inner cortex Na+ -ATPase activity through AT2 receptor. Regulatory Peptides 2004, 120:167-175.
57. DelliPizzi A.M., Hilchey S.D., Bell-Quilley C.P. Natriuretic action of angiotensin(1-7). British Journal of Pharmacology 1994, 111:1-3.
58. Der S.S., Grobe J.L., Yuan L., Narielwala D.R., Walter G.A., Katovich M.J., et al. Cardiac overexpression of angiotensin converting enzyme 2 protects the heart from ischemia-induced pathophysiology. Hypertension 2008, 51:712-718.
59. Dharmani M., Mustafa M.R., Achike F.I., Sim M.K. Effects of angiotensin 1-7 on the actions of angiotensin II in the renal and mesenteric vasculature of hypertensive and streptozotocin-induced diabetic rats. European Journal of Pharmacology 2007, 561:144-150.
60. Dias-Peixoto M.F., Santos R.A., Gomes E.R., Alves M.N., Almeida P.W., Greco L., et al. Molecular mechanisms involved in the angiotensin-(1-7)/mas signaling pathway in cardiomyocytes. Hypertension 2008, 52:542-548.
61. Diez-Freire C., Vazquez J., Correa de Adjounian M.F., Ferrari M.F., Yuan L., Silver X., et al. ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR. Physiological Genomics 2006, 27:12-19.
62. Dilauro M., Zimpelmann J., Robertson S.J., Genest D., Burns K.D. The effect of ACE2 and angiotensin-(1-7) in a mouse model of early chronic kidney disease. American Journal of Physiology-Renal Physiology 2010, 298(6):F1523-F1532.
63. Diz D.I., Falgui B., Bosch S.M., Westwood B.M., Kent J., Ganten D., et al. Hypothalamic substance P release. Attenuated angiotensin responses in mRen2(27) transgenic rats. Hypertension 1997, 29:510-513.
64. Diz D.I., Ferrario C.M. Angiotensin receptor heterogeneity in the dorsal medulla oblongata as defined by angiotensin-(1-7). Advances in Experimental Medicine and Biology 1996, 396:225-235.
65. Diz D.I., Garcia-Espinosa M.A., Gallagher P.E., Ganten D., Ferrario C.M., Averill D.B. Angiotensin-(1-7) and baroreflex function in nucleus tractus solitarii of (mRen2)27 transgenic rats. Journal of Cardiovascular Pharmacology 2008, 51:542-548.
66. Diz D.I., Pirro N.T. Differential actions of angiotensin II and angiotensin-(1-7) on transmitter release. Hypertension 1992, 19:II41-II48.
67. Dong B., Zhang C., Feng J.B., Zhao Y.X., Li S.Y., Yang Y.P., et al. Overexpression of ACE2 enhances plaque stability in a rabbit model of atherosclerosis. Arteriosclerosis. Thrombosis, and Vascular Biology 2008, 28:1270-1276.
68. Donoghue M., Hsieh F., Baronas E., Godbout K., Gosselin M., Stagliano N., et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circulation Research 2000, 87:E1-E9.
69. Douglas G.C., O'Bryan M.K., Hedger M.P., Lee D.K., Yarski M.A., Smith A.I., et al. The novel angiotensin-converting enzyme (ACE) homolog, ACE2, is selectively expressed by adult leydig cells of the testis. Endocrinology 2004, 145:4703-4711.
70. Ebermann L., Spillmann F., Sidiropoulos M., Escher F., Heringer-Walther S., Schultheiss H.P., et al. The angiotensin-(1-7) receptor agonist AVE0991 is cardioprotective in diabetic rats. European Journal of Pharmacology 2008, 590:276-280.
71. Ebihara F., Di Marco G.S., Juliano M.A., Casarini D.E. Neutral endopeptidase expression in mesangial cells. Journal of the Renin-Angiotensin-Aldosterone System 2003, 4:228-233.
72. Edwards R.M., Pullen M., Nambi P. Distribution of neutral endopeptidase activity along the rat and rabbit nephron. Pharmacology 1999, 59:45-50.
73. Ellefson D.D., Dizerega G.S., Espinoza T., Roda N., Maldonado S., Rodgers K.E. Synergistic effects of co-administration of angiotensin 1-7 and neupogen on hematopoietic recovery in mice. Cancer Chemotherapy Pharmacology 2004, 53:15-24.
74. Epelman S., Tang W.H., Chen S.Y., Van L.F., Francis G.S., Sen S. Detection of soluble angiotensin-converting enzyme 2 in heart failure: Insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system. Journal of the American College of Cardiology 2008, 52:750-754.
75. Esteban V., Heringer-Walther S., Sterner-Kock A., de B.R., van den Engel S., Wang Y., et al. Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation. PloS One 2009, 4:e5406.
76. Fan X., Wang Y., Sun K., Zhang W., Yang X., Wang S., et al. Polymorphisms of ACE2 gene are associated with essential hypertension and antihypertensive effects of captopril in women. Clinical Pharmacology and Therapeutics 2007, 82:187-196.
77. Fernandes L., Fortes Z.B., Nigro D., Tostes R.C., Santos R.A., Catelli De Carvalho M.H. Potentiation of bradykinin by angiotensin-(1-7) on arterioles of spontaneously hypertensive rats studied in vivo. Hypertension 2001, 37:703-709.
78. Ferrario C.M. Does angiotensin-(1-7) contribute to cardiac adaptation and preservation of endothelial function in heart failure?. Circulation 2002, 105:1523-1525.
79. Ferrario C.M. Contribution of angiotensin-(1-7) to cardiovascular physiology and pathology. Current Hypertension Reports 2003, 5:129-134.
80. Ferrario C.M. Myocardial infarction increases ACE2 expression in rat and humans. European Heart Journal 2005, 26:1141-1143.
81. Ferrario C.M. New physiological concepts of the renin-angiotensin system from the investigation of precursors and products of angiotensin I metabolism. Hypertension 2010, 55:445-452.
82. Ferrario C.M., Averill D.B., Brosnihan K.B., Chappell M.C., Iskandar S.S., Dean R.H., et al. Vasopeptidase inhibition and ang-(1-7) in the spontaneously hypertensive rat. Kidney International 2002, 62:1349-1357.
83. Ferrario C.M., Chappell M.C., Tallant E.A., Brosnihan K.B., Diz D.I. Counterregulatory actions of angiotensin-(1-7). Hypertension 1997, 30:535-541.
84. Ferrario C.M., Jessup J., Chappell M.C., Averill D.B., Brosnihan K.B., Tallant E.A., et al. Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation 2005, 111:2605-2610.
85. Ferrario C.M., Jessup J., Gallagher P.E., Averill D.B., Brosnihan K.B., Ann T.E., et al. Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors. Kidney International 2005, 68:2189-2196.
86. Ferrario C.M., Martell N., Yunis C., Flack J.M., Chappell M.C., Brosnihan K.B., et al. Characterization of angiotensin-(1-7) in the urine of normal and essential hypertensive subjects. American Journal of Hypertension 1998, 11:137-146.
87. Ferrario C.M., Smith R.D., Brosnihan B., Chappell M.C., Campese V.M., Vesterqvist O., et al. Effects of omapatrilat on the renin-angiotensin system in salt-sensitive hypertension. American Journal of Hypertension 2002, 15:557-564.
88. Ferrario C.M., Trask A.J., Jessup J.A. Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. American Journal of Physiology-Heart and Circulatory Physiology 2005, 289:H2281-H2290.
89. Ferrario C.M., Varagic J. The ang-(1-7)/ACE2/mas axis in the regulation of nephron function. American Journal of Physiology-Renal Physiology 2010, 298:F1297-F1305.
90. Ferreira A.J., Castro C.H., Guatimosim S., Almeida P.W., Gomes E.R., Dias-Peixoto M.F., et al. Attenuation of isoproterenol-induced cardiac fibrosis in transgenic rats harboring an angiotensin-(1-7)-producing fusion protein in the heart. Therapeutic Advances in Cardiovascular Disease 2010, 4:83-96.
91. Ferreira A.J., Jacoby B.A., Araujo C.A., Macedo F.A., Silva G.A., Almeida A.P., et al. The nonpeptide angiotensin-(1-7) receptor mas agonist AVE-0991 attenuates heart failure induced by myocardial infarction. American Journal of Physiology-Heart and Circulatory Physiology 2007, 292:H1113-H1119.
92. Ferreira A.J., Oliveira T.L., Castro M.C., Almeida A.P., Castro C.H., Caliari M.V., et al. Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991. Life Science 2007, 81:916-923.
93. Ferreira A.J., Raizada M.K. Genomic and proteomic approaches for targeting of angiotensin-converting enzyme2 for cardiovascular diseases. Current Opinion in Cardiology 2008, 23:364-369.
94. Ferreira A.J., Santos R.A., Almeida A.P. Angiotensin-(1-7): Cardioprotective effect in myocardial ischemia/reperfusion. Hypertension 2001, 38:665-668.
95. Ferreira A.J., Santos R.A., Almeida A.P. Angiotensin-(1-7) improves the post-ischemic function in isolated perfused rat hearts. Brazilian Journal of Medical and Biological Research 2002, 35:1083-1090.
96. Fraga-Silva R.A., Pinheiro S.V., Goncalves A.C., Alenina N., Bader M., Santos R.A. The antithrombotic effect of angiotensin-(1-7) involves mas-mediated NO release from platelets. Molecular Medicine 2008, 14:28-35.
97. Gallagher P.E., Chappell M.C., Ferrario C.M., Tallant E.A. Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. American Journal of Physiology-Cell Physiology 2006, 290:C420-C426.
98. Gallagher P.E., Ferrario C.M., Tallant E.A. MAP kinase/phosphatase pathway mediates the regulation of ACE2 by angiotensin peptides. American Journal of Physiology-Cell Physiology 2008, 295:C1169-C1174.
99. Gallagher P.E., Ferrario C.M., Tallant E.A. Regulation of ACE2 in cardiac myocytes and fibroblasts. American Journal of Physiology-Heart and Circulatory Physiology 2008, 295:H2373-H2379.
100. Gallagher P.E., Tallant E.A. Inhibition of human lung cancer cell growth by angiotensin-(1-7). Carcinogenesis 2004, 25:2045-2052.
101. Garcia R., Boucher R., Genest J. Tonin activity in rat saliva: Effect of sympathomimetic and parasympathomimetic drugs. Canadian Journal of Physiology and Pharmacology 1976, 54:443-445.
102. Garcia R., Schiffrin E.L., Gutkowska J., Boucher R., Genest J. Reduction of hypertension in one-kidney one-clip rabbits by immunization with tonin. Proceedings of the Society for Experimental Biology and Medicine 1979, 162:245-248.
103. Gava E., Samad-Zadeh A., Zimpelmann J., Bahramifarid N., Kitten G.T., Santos R.A., et al. Angiotensin-(1-7) activates a tyrosine phosphatase and inhibits glucose-induced signalling in proximal tubular cells. Nephrology, Dialysis, Transplantation 2009, 24:1766-1773.
104. Gavras H., Gavras I., Textor S., Volicer L., Brunner H.R., Rucinska E.J. Effect of angiotensin converting enzyme inhibition on blood pressure, plasma renin activity and plasma aldosterone in essential hypertension. The Journal of Clinical Endocrinology and Metabolism 1978, 46:220-226.
105. Gembardt F., Grajewski S., Vahl M., Schultheiss H.P., Walther T. Angiotensin metabolites can stimulate receptors of the mas-related genes family. Molecular and Cellular Biochemistry 2008, 319:115-123.
106. Gembardt F., Sterner-Kock A., Imboden H., Spalteholz M., Reibitz F., Schultheiss H.P., et al. Organ-specific distribution of ACE2 mRNA and correlating peptidase activity in rodents. Peptides 2005, 26:1270-1277.
107. Giani J.F., Gironacci M.M., Munoz M.C., Turyn D., Dominici F.P. Angiotensin-(1-7) has a dual role on growth-promoting signalling pathways in rat heart in vivo by stimulating STAT3 and STAT5a/b phosphorylation and inhibiting angiotensin II-stimulated ERK1/2 and rho kinase activity. Experimental Physiology 2008, 93:570-578.
108. Giani J.F., Munoz M.C., Mayer M.A., Veiras L.C., Arranz C., Taira C.A., et al. Angiotensin-(1-7) improves cardiac remodeling and inhibits growth-promoting pathways in the heart of fructose-fed rats. American Journal of Physiology- Heart and Circulatory Physiology 2010, 298:H1003-H1013.
109. Gilbert J.S., LaMarca B.B., Granger J.P. ACE2 and ANG-(1-7) in the gravid uterus: The new players on the block. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2008, 294:R915-R916.
110. Gilbert J.S., Ryan M.J., LaMarca B.B., Sedeek M., Murphy S.R., Granger J.P. Pathophysiology of hypertension during preeclampsia: Linking placental ischemia with endothelial dysfunction. American Journal of Physiology-Heart and Circulatory Physiology 2008, 294:H541-H550.
111. Gironacci M.M., Fernandez-Tome M.C., Speziale E., Sterin-Speziale N., Pena C. Enhancement of phosphatidylcholine biosynthesis by angiotensin-(1-7) in the rat renal cortex. Biochemical Pharmacology 2002, 63:507-514.
112. Gomes E.R., Lara A.A., Almeida P.W., Guimaraes D., Resende R.R., Campagnole-Santos M.J., et al. Angiotensin-(1-7) prevents cardiomyocyte pathological remodeling through a nitric oxide/guanosine 3',5'-cyclic monophosphate-dependent pathway. Hypertension 2010, 55:153-160.
113. Gorelik G., Carbini L.A., Scicli A.G. Angiotensin 1-7 induces bradykinin-mediated relaxation in porcine coronary artery. The Journal of Pharmacology and Experimental Therapeutics 1998, 286:403-410.
114. Goulter A.B., Goddard M.J., Allen J.C., Clark K.L. ACE2 gene expression is up-regulated in the human failing heart. BMC Medicine 2004, 2:19.
115. Greene L.J., Spadaro A.C., Martins A.R., Perussi De Jesus W.D., Camargo A.C. Brain endo-oligopeptidase B: A post-proline cleaving enzyme that inactivates angiotensin I and II. Hypertension 1982, 4:178-184.
116. Grobe J.L., Der S.S., Stewart J.M., Meszaros J.G., Raizada M.K., Katovich M.J. ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts. Clinical Science (London) 2007, 113:357-364.
117. Grobe J.L., Mecca A.P., Lingis M., Shenoy V., Bolton T.A., Machado J.M., et al. Prevention of angiotensin II-induced cardiac remodeling by angiotensin-(1-7). American Journal of Physiology- Heart and Circulatory Physiology 2007, 292:H736-H742.
118. Grobe J.L., Mecca A.P., Mao H., Katovich M.J. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. American Journal of Physiology-Heart and Circulatory Physiology 2006, 290:H2417-H2423.
119. Gurley S.B., Coffman T.M. Angiotensin-converting enzyme 2 gene targeting studies in mice: Mixed messages. Experimental Physiology 2008, 93:538-542.
120. Guy J.L., Jackson R.M., Acharya K.R., Sturrock E.D., Hooper N.M., Turner A.J. Angiotensin-converting enzyme-2 (ACE2): Comparative modeling of the active site, specificity requirements, and chloride dependence. Biochemistry 2003, 42:13185-13192.
121. Gwathmey T.M., Pendergrass K.D., Reid S.D., Rose J.C., Diz D.I., Chappell M.C. Angiotensin-(1-7)-angiotensin-converting enzyme 2 attenuates reactive oxygen species formation to angiotensin II within the cell nucleus. Hypertension 2010, 55:166-171.
122. Hamming I., Timens W., Bulthuis M.L., Lely A.T., Navis G.J., Van G.H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. The Journal of Pathology 2004, 203:631-637.
123. Hamming I., Van G.H., Turner A.J., Rushworth C.A., Michaud A.A., Corvol P., et al. Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats. Experimental Physiology 2008, 93:631-638.
124. Handa R.K., Ferrario C.M., Strandhoy J.W. Renal actions of angiotensin-(1-7): In vivo and in vitro studies. The American Journal of Physiology 1996, 270:F141-F147.
125. He J.G., Huang Y.Y., Ma H., He X.H., Liao X.X., Wang L.C., et al. Effects of angiotensin-(1-7) on remodeling of myocardial collagen network in pressure-overloaded rats (article in Chinese). Zhongguo Wei Zhong Bing Ji Jiu Yi Xue 2004, 16:523-526.
126. Heeneman S., Sluimer J.C., Daemen M.J. Angiotensin-converting enzyme and vascular remodeling. Circulation Research 2007, 101:441-454.
127. Heitsch H., Brovkovych S., Malinski T., Wiemer G. Angiotensin-(1-7)-stimulated nitric oxide and superoxide release from endothelial cells. Hypertension 2001, 37:72-76.
128. Heller J., Kramer H.J., Maly J., Cervenka L., Horacek V. Effect of intrarenal infusion of angiotensin-(1-7) in the dog. Kidney & Blood Pressure Research 2000, 23:89-94.
129. Herath C.B., Lubel J.S., Jia Z., Velkoska E., Casley D., Brown L., et al. Portal pressure responses and angiotensin peptide production in rat liver are determined by relative activity of ACE and ACE2. American Journal of Physiology-Gastrointestinal and Liver Physiology 2009, 297:G98-G106.
130. Herath C.B., Warner F.J., Lubel J.S., Dean R.G., Jia Z., Lew R.A., et al. Upregulation of hepatic angiotensin-converting enzyme 2 (ACE2) and angiotensin-(1-7) levels in experimental biliary fibrosis. Journal of Hepatology 2007, 47:387-395.
131. Heringer-Walther S., Eckert K., Schumacher S.M., Uharek L., Wulf-Goldenberg A., Gembardt F., et al. Angiotensin-(1-7) stimulates hematopoietic progenitor cells in vitro and in vivo. Haematologica 2009, 94:857-860.
132. Hu X.S., Xie X.D., Wang X.X., Zeng C.L., Ni Y.M., Yu G.W., et al. Effects of angiotensin converting enzyme inhibitor on the expression of angiotensin converting enzyme 2 in atrium of patients with atrial fibrillation (article in Chinese). Zhonghua Xin Xue Xguan Bing Za Zhi 2007, 35:625-628.
133. Huang W., Yang W., Wang Y., Zhao Q., Gu D., Chen R. Association study of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms and essential hypertension in northern han chinese. Journal of Human Hypertension 2006, 20:968-971.
134. Huentelman M.J., Grobe J.L., Vazquez J., Stewart J.M., Mecca A.P., Katovich M.J., et al. Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats. Experimental Physiology 2005, 90:783-790.
135. Igase M., Kohara K., Nagai T., Miki T., Ferrario C.M. Increased expression of angiotensin converting enzyme 2 in conjunction with reduction of neointima by angiotensin II type 1 receptor blockade. Hypertension Research 2008, 31:553-559.
136. Igase M., Strawn W.B., Gallagher P.E., Geary R.L., Ferrario C.M. Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats. American Journal of Physiology-Heart and Circulatory Physiology 2005, 289:H1013-H1019.
137. Ishiyama Y., Gallagher P.E., Averill D.B., Tallant E.A., Brosnihan K.B., Ferrario C.M. Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors. Hypertension 2004, 43:970-976.
138. Iwata M., Cowling R.T., Gurantz D., Moore C., Zhang S., Yuan J.X., et al. Angiotensin-(1-7) binds to specific receptors on cardiac fibroblasts to initiate antifibrotic and antitrophic effects. American Journal of Physiology-Heart and Circulatory Physiology 2005, 289:H2356-H2363.
139. Iyer S.N., Chappell M.C., Averill D.B., Diz D.I., Ferrario C.M. Vasodepressor actions of angiotensin-(1-7) unmasked during combined treatment with lisinopril and losartan. Hypertension 1998, 31:699-705.
140. Jaiswal N., Diz D.I., Chappell M.C., Khosla M.C., Ferrario C.M. Stimulation of endothelial cell prostaglandin production by angiotensin peptides. Characterization of receptors. Hypertension 1992, 19:II49-II55.
141. Jessup J.A., Gallagher P.E., Averill D.B., Brosnihan K.B., Tallant E.A., Chappell M.C., et al. Effect of angiotensin II blockade on a new congenic model of hypertension derived from transgenic ren-2 rats. American Journal of Physiology-Heart and Circulatory Physiology 2006, 291:H2166-H2172.
142. Ji H., Menini S., Zheng W., Pesce C., Wu X., Sandberg K. Role of angiotensin-converting enzyme 2 and angiotensin(1-7) in 17beta-oestradiol regulation of renal pathology in renal wrap hypertension in rats. Experimental Physiology 2008, 93:648-657.
143. Joyner J., Neves L., Ferrario C., Brosnihan K. Administration of D-alanine-[ang-(1-7)] (A-779) Prior To pregnancy in sprague dawley rats produces antidiuresis in late gestation. Journal of the American Society of Hypertension 2008, 2:425-430.
144. Joyner J., Neves L.A., Granger J.P., Alexander B.T., Merrill D.C., Chappell M.C., et al. Temporal-spatial expression of ANG-(1-7) and angiotensin-converting enzyme 2 in the kidney of normal and hypertensive pregnant rats. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2007, 293:R169-R177.
145. Kaiqiang J., Minakawa M., Fukui K., Suzuki Y., Fukuda I. Olmesartan improves left ventricular function in pressure-overload hypertrophied rat heart by blocking angiotensin II receptor with synergic effects of upregulation of angiotensin converting enzyme 2. Therapeutic Advances in Cardiovascular Disease 2009, 3:103-111.
146. Kassiri Z., Zhong J., Guo D., Basu R., Wang X., Liu P.P., et al. Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circulation: Heart Failure 2009, 2:446-455.
147. Kato T., Okada M., Nagatsu T. Distribution of post-proline cleaving enzyme in human brain and the peripheral tissues. Molecular and Cellular Biochemistry 1980, 32:117-121.
148. Katovich M.J., Grobe J.L., Huentelman M., Raizada M.K. Angiotensin-converting enzyme 2 as a novel target for gene therapy for hypertension. Experimental Physiology 2005, 90:299-305.
149. Keidar S., Strizevsky A., Raz A., Gamliel-Lazarovich A. ACE2 activity is increased in monocyte-derived macrophages from prehypertensive subjects. Nephrology, Dialysis, Transplantation 2007, 22:597-601.
150. Khairallah P.A., Khosla M.C., Bumpus F.M., Tait J.F., Tait S.A. Steroidogenic and pressor activity of angiotensin analogues in the rat. Clinical Science and. Molecular Medicine Supplement 1978, 4:175s-177s.
151. Khairallah P.A., Toth A., Bumpus F.M. Analogs of angiotensin II. II. Mechanism of receptor interaction. Journal of Medicinal Chemistry 1970, 13:181-184.
152. Khosla M.C., Hall M.M., Munoz-Ramirez H., Khairallah P.A., Bumpus F.M. Synthesis of [1-sarcosine, 8-O-methylserine]angiotensin II and 1-substituted analogues of [8-threonine]angiotensin II as antagonists of angiotensin II. Journal of Medicinal Chemistry 1977, 20:253-256.
153. Khosla M.C., Hall M.M., Smeby R.R., Bumpus F.M. Factors that influence the antagonistic properties of angiotensin II antagonists. Journal of Medicinal Chemistry 1973, 16:829-832.
154. Khosla M.C., Hall M.M., Smeby R.R., Bumpus F.M. Agonist and antagonist relationships in 1- and 8-substituted analogs of angiotensin II. Journal of Medicinal Chemistry 1974, 17:1156-1160.
155. Khosla M.C., Leese R.A., Maloy W.L., Ferreira A.T., Smeby R.R., Bumpus F.M. Synthesis of some analogs of angiotensin II as specific antagonists of the parent hormone. Journal of Medicinal Chemistry 1972, 15:792-795.
156. Khosla M.C., Munoz-Ramirez H., Hall M.M., Smeby R.R., Khairallah P.A., Bumpus F.M., et al. Synthesis of angiotensin II antagonists containing N- and O-methylated and other amino acid residues. Journal of Medicinal Chemistry 1976, 19:244-250.
157. Koka V., Huang X.R., Chung A.C., Wang W., Truong L.D., Lan H.Y. Angiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway. The American Journal of Pathology 2008, 172:1174-1183.
158. Komatsu T., Suzuki Y., Imai J., Sugano S., Hida M., Tanigami A., et al. Molecular cloning, mRNA expression and chromosomal localization of mouse angiotensin-converting enzyme-related carboxypeptidase (mACE2). DNA Sequence 2002, 13:217-220.
159. Konoshita T., Wakahara S., Mizuno S., Motomura M., Aoyama C., Makino Y., et al. Tissue gene expression of renin-angiotensin system in human type 2 diabetic nephropathy. Diabetes Care 2006, 29:848-852.
160. Kozlovski V.I., Lomnicka M., Fedorowicz A., Chlopicki S. On the mechanism of coronary vasodilation induced by angiotensin-(1-7) in the isolated guinea pig heart. Basic & Clinical Pharmacology & Toxicology 2007, 100:361-365.
161. Kucharewicz I., Pawlak R., Matys T., Pawlak D., Buczko W. Antithrombotic effect of captopril and losartan is mediated by angiotensin-(1-7). Hypertension 2002, 40:774-779.
162. Langeveld B.E., Henning R.H., de Smet B.J., Zijlstra F., Driessen A., Tijsma E., et al. Rescue of arterial function by angiotensin-(1-7): Towards improvement of endothelial function by drug-eluting stents. Netherlands Heart Journal 2008, 16:291-292.
163. Langeveld B., van Gilst W.H., Tio R.A., Zijlstra F., Roks A.J. Angiotensin-(1-7) attenuates neointimal formation after stent implantation in the rat. Hypertension 2005, 45:138-141.
164. Lara L.S., Bica R.B., Sena S.L., Correa J.S., Marques-Fernandes M.F., Lopes A.G., et al. Angiotensin-(1-7) reverts the stimulatory effect of angiotensin II on the proximal tubule Na(+)-ATPase activity via a A779-sensitive receptor. Regulatory Peptides 2002, 103:17-22.
165. + ATPase activity by angiotensin-(1-7) in MDCK cells. Regulatory Peptides 2005, 129:221-226.
166. Lely A.T., Hamming I., Van G.H., Navis G.J. Renal ACE2 expression in human kidney disease. The Journal of Pathology 2004, 204:587-593.
167. Lemos V.S., Silva D.M., Walther T., Alenina N., Bader M., Santos R.A. The endothelium-dependent vasodilator effect of the nonpeptide ang(1-7) mimic AVE 0991 is abolished in the aorta of mas-knockout mice. Journal of Cardiovascular Pharmacology 2005, 46:274-279.
168. Li C., Booze R.M., Hersh L.B. Tissue-specific expression of rat neutral endopeptidase mRNAs. Annals of the New York Academy of Sciences 1996, 780:145-155.
169. Li P., Chappell M.C., Ferrario C.M., Brosnihan K.B. Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. Hypertension 1997, 29:394-400.
170. Li P., Ferrario C.M., Ganten D., Brosnihan K.B. Chronic estrogen treatment in female transgenic (mRen2)27 hypertensive rats augments endothelium-derived nitric oxide release. American Journal of Hypertension 1997, 10:662-670.
171. Li Y., Wu J., He Q., Shou Z., Zhang P., Pen W., et al. Angiotensin (1-7) prevent heart dysfunction and left ventricular remodeling caused by renal dysfunction in 5/6 nephrectomy mice. Hypertension Research 2009, 32:369-374.
172. Li N., Zimpelmann J., Cheng K., Wilkins J.A., Burns K.D. The role of angiotensin converting enzyme 2 in the generation of angiotensin 1-7 by rat proximal tubules. American Journal of Physiology-Renal Physiology 2005, 288:F353-F362.
173. Lieb W., Graf J., Gotz A., Konig I.R., Mayer B., Fischer M., et al. Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA augsburg echocardiographic substudy. Journal of Molecular Medicine 2006, 84:88-96.
174. Lin C.S., Pan C.H., Wen C.H., Yang T.H., Kuan T.C. Regulation of angiotensin converting enzyme II by angiotensin peptides in human cardiofibroblasts. Peptides 2010, 31(7):1334-1340.
175. Liu T.B., Shang H.P., Zhang K.X., Chen L.H., Zhu X.L., Zhang Y., et al. Association of angiotensin I converting enzyme 2 gene polymorphism with essential hypertension (article in Chinese). Zhonghua xin xue guan bing za zhi 2005, 22:569-571.
176. Loot A.E., Roks A.J., Henning R.H., Tio R.A., Suurmeijer A.J., Boomsma F., et al. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002, 105:1548-1550.
177. Lovren F., Pan Y., Quan A., Teoh H., Wang G., Shukla P.C., et al. Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis. American Journal of Physiology- Heart and Circulatory Physiology 2008, 295:H1377-H1384.
178. Lubel J.S., Herath C.B., Burrell L.M., Angus P.W. Liver disease and the renin-angiotensin system: Recent discoveries and clinical implications. Journal of Gastroenterology and Hepatology 2008, 23:1327-1338.
179. Lubel J.S., Herath C.B., Tchongue J., Grace J., Jia Z., Spencer K., et al. Angiotensin-(1-7), an alternative metabolite of the renin-angiotensin system, is up-regulated in human liver disease and has antifibrotic activity in the bile-duct-ligated rat. Clinical Science (London) 2009, 117:375-386.
180. Luque M., Martin P., Martell N., Fernandez C., Brosnihan K.B., Ferrario C.M. Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension. Journal of Hypertension 1996, 14:799-805.
181. Machado R.D., Ferreira M.A., Belo A.V., Santos R.A., Andrade S.P. Vasodilator effect of angiotensin-(1-7) in mature and sponge-induced neovasculature. Regulatory Peptides 2002, 107:105-113.
182. Marangoni R.A., Carmona A.K., Passaglia R.C., Nigro D., Fortes Z.B., de Carvalho M.H. Role of the kallikrein-kinin system in ang-(1-7)-induced vasodilation in mesenteric arterioles of wistar rats studied in vivo-in situ. Peptides 2006, 27:1770-1775.
183. Masaki Z., Ferrario C.M., Bumpus F.M., Bravo E.L., Khosla M.C. The course of arterial pressure and the effect of sar1-thr8-angiotensin II in a new model of two-kidney hypertension in conscious dogs. Clinical Science and Molecular Medicine 1977, 52:163-170.
184. McMurray J., Davie A.P. Angiotensin-(1-7) attenuates the development of heart failure after myocardial infarction in rats. Circulation 2002, 106:e147.
185. Mendes A.C., Ferreira A.J., Pinheiro S.V., Santos R.A. Chronic infusion of angiotensin-(1-7) reduces heart angiotensin II levels in rats. Regulatory Peptides 2005, 125:29-34.
186. Meng W., Busija D.W. Comparative effects of angiotensin-(1-7) and angiotensin II on piglet pial arterioles. Stroke 1993, 24:2041-2044.
187. Menon J., Soto-Pantoja D.R., Callahan M.F., Cline J.M., Ferrario C.M., Tallant E.A., et al. Angiotensin-(1-7) inhibits growth of human lung adenocarcinoma xenografts in nude mice through a reduction in cyclooxygenase-2. Cancer Research 2007, 67:2809-2815.
188. Mercure C., Yogi A., Callera G.E., Aranha A.B., Bader M., Ferreira A.J., et al. Angiotensin(1-7) blunts hypertensive cardiac remodeling by a direct effect on the heart. Circulation Research 2008, 103:1319-1326.
189. Merrill D.C., Karoly M., Chen K., Ferrario C.M., Brosnihan K.B. Angiotensin-(1-7) in normal and preeclamptic pregnancy. Endocrine 2002, 18:239-245.
190. Mizuiri S., Hemmi H., Arita M., Ohashi Y., Tanaka Y., Miyagi M., et al. Expression of ACE and ACE2 in individuals with diabetic kidney disease and healthy controls. American Journal of Kidney Diseases 2008, 51:613-623.
191. Mo Y.J., Huang W.H., Chen D.L., Chen F.R. Relationship of angiotensin-converting enzyme 2 gene polymorphism with the prognosis of hypertensive stroke patients (article in Chinese). Nan Fang Yi Ke Da Xue Xue Bao 2010, 30:84-87.
192. Moon J.Y., Jeong K.H., Lee S.H., Lee T.W., Ihm C.G., Lim S.J. Renal ACE and ACE2 expression in early diabetic rats. Nephron Experimental Nephrology 2008, 110:e8-e16.
193. Moriguchi A., Tallant E.A., Matsumura K., Reilly T.M., Walton H., Ganten D., et al. Opposing actions of angiotensin-(1-7) and angiotensin II in the brain of transgenic hypertensive rats. Hypertension 1995, 25:1260-1265.
194. Nasjletti A., Masson G.M. Studies on angiotensinogen formation in a liver perfusion system. Circulation Research 1972, 31(Suppl. 20).
195. Natesh R., Schwager S.L., Sturrock E.D., Acharya K.R. Crystal structure of the human angiotensin-converting enzyme-lisinopril complex. Nature 2003, 421:551-554.
196. Neves L.A., Almeida A.P., Khosla M.C., Campagnole-Santos M.J., Santos R.A. Effect of angiotensin-(1-7) on reperfusion arrhythmias in isolated rat hearts. Brazilian Journal of Medical and Biological Research 1997, 30:801-809.
197. Neves L.A., Averill D.B., Ferrario C.M., Aschner J.L., Brosnihan K.B. Vascular responses to angiotensin-(1-7) during the estrous cycle. Endocrine 2004, 24:161-165.
198. Neves L.A., Stovall K., Joyner J., Valdes G., Gallagher P.E., Ferrario C.M., et al. ACE2 and ANG-(1-7) in the rat uterus during early and late gestation. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2008, 294:R151-R161.
199. Neves L.A., Williams A.F., Averill D.B., Ferrario C.M., Walkup M.P., Brosnihan K.B. Pregnancy enhances the angiotensin (ang)-(1-7) vasodilator response in mesenteric arteries and increases the renal concentration and urinary excretion of ang-(1-7). Endocrinology 2003, 144:3338-3343.
200. Nie W., Yan H., Li S., Zhang Y., Yu F., Zhu W., et al. Angiotensin-(1-7) enhances angiotensin II induced phosphorylation of ERK1/2 in mouse bone marrow-derived dendritic cells. Molecular Immunology 2009, 46:355-361.
201. Nishimura H., Tsuji H., Masuda H., Kasahara T., Yoshizumi M., Sugano T., et al. The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells. Thrombosis and Haemostasis 1999, 82:1516-1521.
202. Niu W., Qi Y., Hou S., Zhou W., Qiu C. Correlation of angiotensin-converting enzyme 2 gene polymorphisms with stage 2 hypertension in han chinese. Translational Research 2007, 150:374-380.
203. Nogueira A.I., Souza Santos R.A., Simoes e Silva A.C., Cabral A.C., Vieira R.L., Drumond T.C., et al. The pregnancy-induced increase of plasma angiotensin-(1-7) is blunted in gestational diabetes. Regulatory Peptides 2007, 141:55-60.
204. Oelkers W.K. Effects of estrogens and progestogens on the renin-aldosterone system and blood pressure. Steroids 1996, 61:166-171.
205. Ognibene D.T., Oliveira P.R., Marins de Carvalho L.C., Costa C.A., Espinoza L.A., Criddle D.N., et al. Angiotensin II-mediated vasodilation is reduced in adult spontaneously hypertensive rats despite enhanced expression of AT2 receptors. Clinical and Experimental Pharmacology & Physiology 2009, 36:12-19.
206. Ohtsuki M., Morimoto S.I., Izawa H., Ismail T.F., Ishibashi-Ueda H., Kato Y., et al. Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure. International Journal of Cardiology 2010, 1-6.
207. Oliveira M.A., Carvalho M.H., Nigro D., Passaglia R.C., Fortes Z.B. Angiotensin-(1-7) and bradykinin interaction in diabetes mellitus: In vivo study. Peptides 2002, 23:1449-1455.
208. Oliveira M.A., Carvalho M.H., Nigro D., Passaglia R.C., Fortes Z.B. Elevated glucose blocks angiotensin-(1-7) and bradykinin interaction: The role of cyclooxygenase products. Peptides 2003, 24:449-454.
209. Oliveira M.A., Fortes Z.B., Santos R.A., Kosla M.C., de Carvalho M.H. Synergistic effect of angiotensin-(1-7) on bradykinin arteriolar dilation in vivo. Peptides 1999, 20:1195-1201.
210. Ondetti M.A., Rubin B., Cushman D.W. Design of specific inhibitors of angiotensin-converting enzyme: New class of orally active antihypertensive agents. Science 1977, 196:441-444.
211. Osei S.Y., Ahima R.S., Minkes R.K., Weaver J.P., Khosla M.C., Kadowitz P.J. Differential responses to angiotensin-(1-7) in the feline mesenteric and hindquarters vascular beds. European Journal of Pharmacology 1993, 234:35-42.
212. Oudit G.Y., Herzenberg A.M., Kassiri Z., Wong D., Reich H., Khokha R., et al. Loss of angiotensin-converting enzyme-2 leads to the late development of angiotensin II-dependent glomerulosclerosis. The American Journal of Pathology 2006, 168:1808-1820.
213. Oudit G.Y., Liu G.C., Zhong J., Basu R., Chow F.L., Zhou J., et al. Human recombinant ACE2 reduces the progression of diabetic nephropathy. Current Medical Literature-Diabetes 2010, 59:529-538.
214. Palmer B.R., Jarvis M.D., Pilbrow A.P., Ellis K.L., Frampton C.M., Skelton L., et al. Angiotensin-converting enzyme 2 A1075G polymorphism is associated with survival in an acute coronary syndromes cohort. American Heart Journal 2008, 156:752-758.
215. Pan C.H., Lin J.L., Lai L.P., Chen C.L., Stephen Huang S.K., Lin C.S. Downregulation of angiotensin converting enzyme II is associated with pacing-induced sustained atrial fibrillation. FEBS Letters 2007, 581:526-534.
216. Pendergrass K.D., Pirro N.T., Westwood B.M., Ferrario C.M., Brosnihan K.B., Chappell M.C. Sex differences in circulating and renal angiotensins of hypertensive mRen(2). Lewis but not normotensive Lewis rats. American Journal of Physiology-Heart and Circulatory Physiology 2008, 295:H10-H20.
217. Pereira R.M., dos Santos R.A., Teixeira M.M., Leite V.H., Costa L.P., da Costa Dias F.L., et al. The renin-angiotensin system in a rat model of hepatic fibrosis: Evidence for a protective role of angiotensin-(1-7). Journal of Hepatology 2007, 46:674-681.
218. Pignone A., Rosso A.D., Brosnihan K.B., Perfetto F., Livi R., Fiori G., et al. Reduced circulating levels of angiotensin-(1-7) in systemic sclerosis: A new pathway in the dysregulation of endothelial-dependent vascular tone control. Annals of the Rheumatic Diseases 2007, 66:1305-1310.
219. Pinheiro S.V., Ferreira A.J., Kitten G.T., da Silveira K.D., da Silva D.A., Santos S.H., et al. Genetic deletion of the angiotensin-(1-7) receptor mas leads to glomerular hyperfiltration and microalbuminuria. Kidney International 2009, 75:1184-1193.
220. Pinheiro S.V., Simoes e Silva A.C., Sampaio W.O., de Paula R.D., Mendes E.P., Bontempo E.D., et al. Nonpeptide AVE 0991 is an angiotensin-(1-7) receptor mas agonist in the mouse kidney. Hypertension 2004, 44:490-496.
221. Polizio A.H., Gironacci M.M., Tomaro M.L., Pena C. Angiotensin-(1-7) blocks the angiotensin II-stimulated superoxide production. Pharmacological Research 2007, 56:86-90.
222. Rajendran S., Chirkov Y.Y., Campbell D.J., Horowitz J.D. Angiotensin-(1-7) enhances anti-aggregatory effects of the nitric oxide donor sodium nitroprusside. Journal of Cardiovascular Pharmacology 2005, 46:459-463.
223. Rajendran S., Chirkov Y.Y., Horowitz J.D. Potentiation of platelet responsiveness to nitric oxide by angiotensin-(1-7) is associated with suppression of superoxide release. Platelets 2007, 18:158-164.
224. Rastelli V.M., Oliveira M.A., Dos S.R., de Cassia Tostes P.R., Nigro D., de Carvalho M.H., et al. Lack of potentiation of bradykinin by angiotensin-(1-7) in a type 2 diabetes model: Role of insulin. Peptides 2007, 28:1040-1049.
225. Reich H.N., Oudit G.Y., Penninger J.M., Scholey J.W., Herzenberg A.M. Decreased glomerular and tubular expression of ACE2 in patients with type 2 diabetes and kidney disease. Kidney International 2008, 74:1610-1616.
226. Ren Y., Garvin J.L., Carretero O.A. Vasodilator action of angiotensin-(1-7) on isolated rabbit afferent arterioles. Hypertension 2002, 39:799-802.
227. Rice G.I., Thomas D.A., Grant P.J., Turner A.J., Hooper N.M. Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. The Biochemical Journal 2004, 383:45-51.
228. Rigat B., Hubert C., henc-Gelas F., Cambien F., Corvol P., Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. The Journal of Clinical Investigation 1990, 86:1343-1346.
229. Rodgers K.E., Oliver J., Dizerega G.S. Phase I/II dose escalation study of angiotensin 1-7 [A(1-7)] administered before and after chemotherapy in patients with newly diagnosed breast cancer. Cancer Chemotherapy Pharmacology 2006, 57:559-568.
230. Rodgers K.E., Xiong S., Dizerega G.S. Accelerated recovery from irradiation injury by angiotensin peptides. Cancer Chemotherapy Pharmacology 2002, 49:403-411.
231. Rodgers K., Xiong S., Dizerega G.S. Effect of angiotensin II and angiotensin(1-7) on hematopoietic recovery after intravenous chemotherapy. Cancer Chemotherapy Pharmacology 2003, 51:97-106.
232. Rosenfeld C.R. Mechanisms regulating angiotensin II responsiveness by the uteroplacental circulation. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology 2001, 281:R1025-R1040.
233. Sakima A., Averill D.B., Gallagher P.E., Kasper S.O., Tommasi E.N., Ferrario C.M., et al. Impaired heart rate baroreflex in older rats: Role of endogenous angiotensin-(1-7) at the nucleus tractus solitarii. Hypertension 2005, 46:333-340.
234. Sampaio W.O., Nascimento A.A., Santos R.A. Systemic and regional hemodynamic effects of angiotensin-(1-7) in rats. American Journal of Physiology-Heart and Circulatory Physiology 2003, 284:H1985-H1994.
235. Sampaio W.O., Souza dos Santos R.A., Faria-Silva R., da Mata Machado L.T., Schiffrin E.L., Touyz R.M. Angiotensin-(1-7) through receptor mas mediates endothelial nitric oxide synthase activation via akt-dependent pathways. Hypertension 2007, 49:185-192.
236. Santiago N.M., Guimaraes P.S., Sirvente R.A., Oliveira L.A., Irigoyen M.C., Santos R.A., et al. Lifetime overproduction of circulating angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling. Hypertension 2010, 55:889-896.
237. Santos S.H., Braga J.F., Mario E.G., Porto L.C., Rodrigues-Machado M.D., Murari A., et al. Improved lipid and glucose metabolism in transgenic rats with increased circulating angiotensin-(1-7). Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 30(5):953-961.
238. Santos R.A., Brum J.M., Brosnihan K.B., Ferrario C.M. The renin-angiotensin system during acute myocardial ischemia in dogs. Hypertension 1990, 15:I121-I127.
239. Santos R.A., Campagnole-Santos M.J., Baracho N.C., Fontes M.A., Silva L.C., Neves L.A., et al. Characterization of a new angiotensin antagonist selective for angiotensin-(1-7): Evidence that the actions of angiotensin-(1-7) are mediated by specific angiotensin receptors. Brain Research Bulletin 1994, 35:293-298.
240. Santos R.A., Castro C.H., Gava E., Pinheiro S.V., Almeida A.P., Paula R.D., et al. Impairment of in vitro and in vivo heart function in angiotensin-(1-7) receptor MAS knockout mice. Hypertension 2006, 47:996-1002.
241. Santos R.A., Ferreira A.J., Nadu A.P., Braga A.N., de Almeida A.P., Campagnole-Santos M.J., et al. Expression of an angiotensin-(1-7)-producing fusion protein produces cardioprotective effects in rats. Physiological Genomics 2004, 17:292-299.
242. Santos R.A., Simoes e Silva A.C., Magaldi A.J., Khosla M.C., Cesar K.R., Passaglio K.T., et al. Evidence for a physiological role of angiotensin-(1-7) in the control of hydroelectrolyte balance. Hypertension 1996, 27:875-884.
243. Santos R.A., Simoes e Silva A.C., Maric C., Silva D.M., Machado R.P., de Buhr I., et al. Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor mas. Proceedings of the National Academy of Sciences of the United States of America 2003, 100:8258-8263.
244. Schiavone M.T., Santos R.A., Brosnihan K.B., Khosla M.C., Ferrario C.M. Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide. Proceedings of the National Academy of Sciences of the United States of America 1988, 85:4095-4098.
245. Schiffrin E.L., Garcia R., Gutkowska J., Boucher R., Genest J. Pressor effect of tonin in anephric animals. Canadian Journal of Physiology and Pharmacology 1981, 59:864-871.
246. Schulz R., Sakane Y., Berry C., Ghai R. Characterisation of neutral endopeptidase 3.4.24.11 (NEP) in the kidney: Comparison between normotensive, genetically hypertensive and experimentally hypertensive rats. Journal of Enzyme Inhibition 1991, 4:347-358.
247. Senador D., Key M., Brosnihan K.B., Irigoyen M.C., Elased K.M., Morris M. Cardiovascular interactions between losartan and fructose in mice. Journal of Cardiovascular Pharmacology and Therapeutics 2010, 15:68-77.
248. Shah D.M. Role of the renin-angiotensin system in the pathogenesis of preeclampsia. American Journal of Physiology-Renal Physiology 2005, 288:F614-F625.
249. Shaltout H.A., Figueroa J.P., Rose J.C., Diz D.I., Chappell M.C. Alterations in circulatory and renal angiotensin-converting enzyme and angiotensin-converting enzyme 2 in fetal programmed hypertension. Hypertension 2009, 53:404-408.
250. Shaltout H.A., Westwood B.M., Averill D.B., Ferrario C.M., Figueroa J.P., Diz D.I., et al. Angiotensin metabolism in renal proximal tubules, urine, and serum of sheep: Evidence for ACE2-dependent processing of angiotensin II. American Journal of Physiology-Renal Physiology 2007, 292:F82-F91.
251. Shiota A., Yamamoto K., Ohishi M., Tatara Y., Ohnishi M., Maekawa Y., et al. Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice. Hypertension Research 2010, 33:298-307.
252. Simoes e Silva A.C., Bello A.P., Baracho N.C., Khosla M.C., Santos R.A. Diuresis and natriuresis produced by long term administration of a selective angiotensin-(1-7) antagonist in normotensive and hypertensive rats. Regulatory Peptides 1998, 74:177-184.
253. Simoes e Silva A.C., Diniz J.S., Pereira R.M., Pinheiro S.V., Santos R.A. Circulating renin angiotensin system in childhood chronic renal failure: Marked increase of angiotensin-(1-7) in end-stage renal disease. Pediatric Research 2006, 60:734-739.
254. Skeggs L.T. Discovery of the two angiotensin peptides and the angiotensin converting enzyme. Hypertension 1993, 21:259-260.
255. Skeggs L.T., Lentz K.E., Kahn J.R., Shumway N.P. The synthesis of a tetradecapeptide renin substrate. The Journal of Experimental Medicine 1958, 108:283-297.
256. Sluimer J.C., Gasc J.M., Hamming I., Van G.H., Michaud A., van den Akker L.H. Angiotensin-converting enzyme 2 (ACE2) expression and activity in human carotid atherosclerotic lesions. The Journal of Pathology 2008, 215:273-279.
257. Smeby R.R., Arakawa K., Bumpus F.M., Marsh M.M. A proposed conformation of isoleucyl-5-angiotensin II. Biochimica et Biophysica Acta 1962, 58:550-557.
258. Soares de M.R., Resende A.C., Emiliano A.F., Tano T., Mendes-Ribeiro A.C., Correia M.L., et al. The role of bradykinin, AT2 and angiotensin 1-7 receptors in the EDRF-dependent vasodilator effect of angiotensin II on the isolated mesenteric vascular bed of the rat. British Journal of Pharmacology 2004, 141:860-866.
259. Soler M.J., Wysocki J., Batlle D. Angiotensin-converting enzyme 2 and the kidney. Experimental Physiology 2008, 93:549-556.
260. Soler M.J., Ye M., Wysocki J., William J., Lloveras J., Batlle D. Localization of ACE2 in the renal vasculature: Amplification by angiotensin II type 1 receptor blockade using telmisartan. American Journal of Physiology-Renal Physiology 2009, 296:F398-F405.
261. Soto-Pantoja D.R., Menon J., Gallagher P.E., Tallant E.A. Angiotensin-(1-7) inhibits tumor angiogenesis in human lung cancer xenografts with a reduction in vascular endothelial growth factor. Molecular Cancer Therapeutics 2009, 8:1676-1683.
262. Sotoodehnia N., Li G., Johnson C.O., Lemaitre R.N., Rice K.M., Rea T.D., et al. Genetic variation in angiotensin-converting enzyme-related pathways associated with sudden cardiac arrest risk. Heart Rhythm 2009, 6:1306-1314.
263. Strawn W.B., Chappell M.C., Dean R.H., Kivlighn S., Ferrario C.M. Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000, 101:1586-1593.
264. Strawn W.B., Ferrario C.M., Tallant E.A. Angiotensin-(1-7) reduces smooth muscle growth after vascular injury. Hypertension 1999, 33:207-211.
265. Strawn W.B., Richmond R.S., Ann T.E., Gallagher P.E., Ferrario C.M. Renin-angiotensin system expression in rat bone marrow haematopoietic and stromal cells. British Journal of Haematology 2004, 126:120-126.
266. Streeten D.H., Anderson G.H., Freiberg J.M., Dalakos T.G. Use of an angiotensin II antagonist (saralasin) in the recognition of "angiotensinogenic" hypertension. The New England Journal of Medicine 1975, 292:657-662.
267. Streeten D.H., Freiberg J.M., Anderson G.H., Dalakos T.G. Identification of angiotensinogenic hypertension in man using 1-sar-8-ala-angiotensin II (saralasin, P-113). Circulation Research 1975, 36:125-132.
268. Su Z., Zimpelmann J., Burns K.D. Angiotensin-(1-7) inhibits angiotensin II-stimulated phosphorylation of MAP kinases in proximal tubular cells. Kidney International 2006, 69:2212-2218.
269. Tallant E.A., Ferrario C.M., Gallagher P.E. Angiotensin-(1-7) inhibits growth of cardiac myocytes through activation of the mas receptor. American Journal of Physiology-Heart and Circulatory Physiology 2005, 289:H1560-H1566.
270. Tallant E.A., Ferrario C.M., Gallagher P.E. Cardioprotective role for angiotensin-(1-7) and angiotensin converting enzyme 2 in the heart. Future Cardiology 2006, 2:335-342.
271. Tikellis C., Bialkowski K., Pete J., Sheehy K., Su Q., Johnston C., et al. ACE2 deficiency modifies renoprotection afforded by ACE inhibition in experimental diabetes. Current Medical Literature-Diabetes 2008, 57:1018-1025.
272. Tikellis C., Johnston C.I., Forbes J.M., Burns W.C., Burrell L.M., Risvanis J., et al. Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy. Hypertension 2003, 41:392-397.
273. Timmermans P.B., Duncia J.V., Carini D.J., Chiu A.T., Wong P.C., Wexler R.R., et al. Discovery of losartan, the first angiotensin II receptor antagonist. Journal of Human Hypertension 1995, 9(Suppl. 5):S3-S18.
274. Timmermans P.B., Wong P.C., Chiu A.T., Herblin W.F., Benfield P., Carini D.J., et al. Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacological Reviews 1993, 45:205-251.
275. Tipnis S.R., Hooper N.M., Hyde R., Karran E., Christie G., Turner A.J. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. The Journal of Biological Chemistry 2000, 275:33238-33243.
276. Tirapelli C.R., Fukada S.Y., de Godoy M.A., de Oliveira A.M. Analysis of the mechanisms underlying the vasorelaxant action of angiotensin II in the isolated rat carotid. Life Science 2006, 78:2676-2682.
277. Towler P., Staker B., Prasad S.G., Menon S., Tang J., Parsons T., et al. ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. The Journal of Biological Chemistry 2004, 279:17996-18007.
278. Trask A.J., Averill D.B., Ganten D., Chappell M.C., Ferrario C.M. Primary role of angiotensin-converting enzyme-2 in cardiac production of angiotensin-(1-7) in transgenic Ren-2 hypertensive rats. American Journal of Physiology-Heart and Circulatory Physiology 2007, 292:H3019-H3024.
279. Trask A.J., Groban L., Westwood B.M., Varagic J., Ganten D., Gallagher P.E., et al. Inhibition of Angiotensin-converting enzyme 2 exacerbates cardiac hypertrophy and fibrosis in Ren-2 hypertensive rats. American Journal of Hypertension 2010, 23:687-693.
280. Valdes G., Germain A.M., Corthorn J., Berrios C., Foradori A.C., Ferrario C.M., et al. Urinary vasodilator and vasoconstrictor angiotensins during menstrual cycle, pregnancy, and lactation. Endocrine 2001, 16:117-122.
281. Valdes G., Neves L.A., Anton L., Corthorn J., Chacon C., Germain A.M., et al. Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies. Placenta 2006, 27:200-207.
282. Varagic J., Ahmad S., Brosnihan K.B., Groban L., Chappell M.C., Tallant E.A., et al. Decreased cardiac Ang-(1-7) is associated with salt-induced cardiac remodeling and dysfunction. Therapeutic Advances in Cardiovascular Disease 2010, 4:17-25.
283. Velez J.C., Ryan K.J., Harbeson C.E., Bland A.M., Budisavljevic M.N., Arthur J.M., et al. Angiotensin I is largely converted to angiotensin (1-7) and angiotensin (2-10) by isolated rat glomeruli. Hypertension 2009, 53:790-797.
284. Velkoska E., Dean R.G., Burchill L., Levidiotis V., Burrell L.M. Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition. Clinical Science (London) 2010, 118:269-279.
285. Velloso E.P., Vieira R., Cabral A.C., Kalapothakis E., Santos R.A. Reduced plasma levels of angiotensin-(1-7) and renin activity in preeclamptic patients are associated with the angiotensin I- converting enzyme deletion/deletion genotype. Brazilian Journal of Medical and Biological Research 2007, 40:583-590.
286. Vickers C., Hales P., Kaushik V., Dick L., Gavin J., Tang J., et al. Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. The Journal of Biological Chemistry 2002, 277:14838-14843.
287. Wang S.X., Fu C.Y., Zou Y.B., Wang H., Shi Y., Xu X.Q., et al. Polymorphisms of angiotensin-converting enzyme 2 gene associated with magnitude of left ventricular hypertrophy in male patients with hypertrophic cardiomyopathy. Chinese Medical Journal 2008, 121:27-31.
288. Wang L.J., He J.G., Ma H., Cai Y.M., Liao X.X., Zeng W.T., et al. Chronic administration of angiotensin-(1-7) attenuates pressure-overload left ventricular hypertrophy and fibrosis in rats. Di 1 Jun Yi Da Xue Xue Bao 2005, 25:481-487.
289. Wang G., Lai F.M., Lai K.B., Chow K.M., Kwan C.H., Li K.T., et al. Urinary mRNA expression of ACE and ACE2 in human type 2 diabetic nephropathy. Diabetologia 2008, 51:1062-1067.
290. Wang G., Lai F.M., Lai K.B., Chow K.M., Kwan C.H., Li K.T., et al. Discrepancy between intrarenal messenger RNA and protein expression of ACE and ACE2 in human diabetic nephropathy. American Journal of Nephrology 2009, 29:524-531.
291. Warner F.J., Lew R.A., Smith A.I., Lambert D.W., Hooper N.M., Turner A.J. Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localized to the apical surface of polarized kidney cells. The Journal of Biological Chemistry 2005, 280:39353-39362.
292. Wong P.C., Hart S.D., Zaspel A.M., Chiu A.T., Ardecky R.J., Smith R.D., et al. Functional studies of nonpeptide angiotensin II receptor subtype-specific ligands: DuP 753 (AII-1) and PD123177 (AII-2). The Journal of Pharmacology and Experimental Therapeutics 1990, 255:584-592.
293. Wysocki J., Gonzalez-Pacheco F.R., Batlle D. Angiotensin-converting enzyme 2: Possible role in hypertension and kidney disease. Current Hypertension Reports 2008, 10:70-77.
294. Wysocki J., Ye M., Rodriguez E., Gonzalez-Pacheco F.R., Barrios C., Evora K., et al. Targeting the degradation of angiotensin II with recombinant angiotensin-converting enzyme 2: Prevention of angiotensin II-dependent hypertension. Hypertension 2010, 55:90-98.
295. Wysocki J., Ye M., Soler M.J., Gurley S.B., Xiao H.D., Bernstein K.E., et al. ACE and ACE2 activity in diabetic mice. Current Medical Literature-Diabetes 2006, 55:2132-2139.
296. Yamada K., Iyer S.N., Chappell M.C., Brosnihan K.B., Fukuhara M., Ferrario C.M. Differential response of angiotensin peptides in the urine of hypertensive animals. Regulatory Peptides 1999, 80:57-66.
297. Yamamoto K., Ohishi M., Katsuya T., Ito N., Ikushima M., Kaibe M., et al. Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II. Hypertension 2006, 47:718-726.
298. Yamamoto M., Turker R.K., Khairallah P.A., Bumpus F.M. A potent competitive antagonist of angiotensin II. European Journal of Pharmacology 1972, 18:316-322.
299. Yan Q.N., Xu C.S., Li Z.L., Zhou P., Ye R.Q., Li M., et al. Relationship of angiotensin-converting enzyme 2 gene polymorphisms and vulnerability to coronary heart disease in patients with type 2 diabetes mellitus (article in Chinese). Nan Fang Yi Ke Da Xue Xue Bao 2008, 28:1365-1368.
300. Yang W., Huang W., Su S., Li B., Zhao W., Chen S., et al. Association study of ACE2 (angiotensin I-converting enzyme 2) gene polymorphisms with coronary heart disease and myocardial infarction in a Chinese Han population. Clinical Science (London) 2006, 111:333-340.
301. Ye M., Wysocki J., William J., Soler M.J., Cokic I., Batlle D. Glomerular localization and expression of Angiotensin-converting enzyme 2 and Angiotensin-converting enzyme: Implications for albuminuria in diabetes. Journal of the American Society of Nephrology 2006, 17:3067-3075.
302. Yi L., Gu Y.H., Wang X.L., An L.Z., Xie X.D., Shao W., et al. Association of ACE, ACE2 and UTS2 polymorphisms with essential hypertension in Han and Dongxiang populations from north-western China. The Journal of International Medical Research 2006, 34:272-283.
303. Yousif M.H., Kehinde E.O., Benter I.F. Different responses to angiotensin-(1-7) in young, aged and diabetic rabbit corpus cavernosum. Pharmacological Research 2007, 56:209-216.
304. Zhang J., Noble N.A., Border W.A., Huang Y. Infusion of angiotensin-(1-7) reduces glomerulosclerosis through counteracting angiotensin II in experimental glomerulonephritis. American Journal of Physiology-Renal Physiology 2010, 298:F579-F588.
305. Zhou L., Zhang R., Yao W., Wang J., Qian A., Qiao M., et al. Decreased expression of angiotensin-converting enzyme 2 in pancreatic ductal adenocarcinoma is associated with tumor progression. The Tohoku Journal of Experimental Medicine 2009, 217:123-131.
306. Zulli A., Burrell L.M., Widdop R.E., Black M.J., Buxton B.F., Hare D.L. Immunolocalization of ACE2 and AT2 receptors in rabbit atherosclerotic plaques. The Journal of Histochemistry and Cytochemistry 2006, 54:147-150.